Profound Medical Corp. | |
Stock Exchange | Other OTC |
EPS |
$0.13 |
Market Cap |
$64.83 M |
Shares Outstanding |
108.04 M |
Public Float |
- |
Address |
2400 Skymark Avenue Mississauga Ontario L4W 5K5 Canada |
Employees | - |
Website | http://www.profoundmedical.com |
Updated | 07/08/2019 |
Profound Medical Corp. engages in developing and commercializing minimally invasive treatments for prostate cancer. It develops Transurethral Ultrasound Ablation-PRO system that completed a Phase I clinical trial, which combines magnetic resonance imaging guidance, and ultrasound energy to deliver thermal ablative therapy to the prostate gland delivered through the urethra. Profound Medical was founded in 2008 and is headquartered in Toronto, CA. |